SECURITIES AND EXCHANGE COMMISSION
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. |
76028W-107 |
Page | 2 |
of | 5 Pages |
1 | NAMES OF REPORTING PERSONS Cardiovascular Systems, Inc. |
||||||||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)* |
||||||||||
(a) o | |||||||||||
(b) o | |||||||||||
3 | SEC USE ONLY | ||||||||||
4 | SOURCE OF FUNDS (SEE INSTRUCTIONS) | ||||||||||
OO (See Item 3) | |||||||||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ||||||||||
þ | |||||||||||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||||||||
Minnesota | |||||||||||
7 | SOLE VOTING POWER | ||||||||||
NUMBER OF | 0 | ||||||||||
SHARES | 8 | SHARED VOTING POWER | |||||||||
BENEFICIALLY | |||||||||||
OWNED BY | 8,789,801 shares of Common Stock (See Items 4 and 5) | ||||||||||
EACH | 9 | SOLE DISPOSITIVE POWER | |||||||||
REPORTING | |||||||||||
PERSON | 0 | ||||||||||
WITH | 10 | SHARED DISPOSITIVE POWER | |||||||||
0 | |||||||||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||||||||
8,789,801 shares of Common Stock | |||||||||||
12 | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | ||||||||||
o | |||||||||||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||||||||
32.4% shares of Common Stock* | |||||||||||
14 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | ||||||||||
CO |
2
3
Dated: December 31, 2008 | CARDIOVASCULAR SYSTEMS, INC. |
|||
By: | /s/ James E. Flaherty | |||
James E. Flaherty | ||||
Chief Administrative Officer and Secretary | ||||
4
Replidyne Common Stock Subject to Voting | ||||||||
Agreement | ||||||||
Name of Voting Agreement Stockholder | Number of Shares | Percentage Ownership | ||||||
Kenneth J. Collins |
360,520 | 1.3 | % | |||||
TPG Biotechnology Partners, L.P.; TPG
Ventures, L.P. |
1,871,982 | 6.9 | % | |||||
HealthCare Ventures VI, L.P.;
HealthCare Ventures VIII, L.P. |
2,964,167 | 10.9 | % | |||||
Sequel Limited Partnership III; Sequel
Entrepreneurs Fund III, L.P. |
986,887 | 3.6 | % | |||||
The Daniel J. Mitchell Trust |
11,336 | * | ||||||
Morgenthaler Partners VII, L.P. |
1,583,200 | 5.8 | % | |||||
Perseus-Soros Biopharmaceutical Fund, LP |
1,011,709 | 3.7 | % |
* | Less than 1% of the outstanding share |
5